Osteopontin: a bona fide mediator of abdominal aortic aneurysm?
Osteopontin: a bona fide mediator of abdominal aortic aneurysm?
复制标题
骨桥蛋白:腹主动脉瘤的真正介质?
DOI:
10.1161/01.atv.0000258640.30287.7b
复制
发表时间:
2007
期刊:
影响因子:
--
通讯作者:
Weintraub,NealL
中科院分区:
文献类型:
--
作者:
Shaheen,Mazen;Weintraub,NealL
Osteopontin is an arginine-glycine–aspartate (RGD) containing adhesive glycoprotein first identified in bone but subsequently detected in many other tissues, including, dentin, cartilage, kidney, and vascular tissues. 1–3 It is expressed by a wide variety of inflammatory cells (eg, macrophages, T lymphocytes, NK cells), and, to a lesser extent, by endothelial cells and smooth muscle cells. The RGD domain facilitates tissue binding of osteopontin to various extracellular matrix proteins, such as αvß3 integrin and fibronectin. Additionally, osteopontin may engage CD44 through an RGD-independent mechanism. In extracellular fluids, osteopontin functions as a cytokine, and its plasma levels are increased in autoimmune diseases such as lupus, rheumatoid arthritis, and multiple sclerosis. 4 The diverse biological actions of osteopontin could potentially regulate many processes pertinent to vascular disease, including inflammation, cell adhesion, viability, angiogenesis, and calcification (Figure). 5, 6 Such actions may underlie its presumed role in the pathophysiology of atherosclerosis and in modulating arteriopathy associated with diabetes and chronic renal failure (reviewed by Johnson et al7). Of relevance to the present topic, Bruemmer et al reported that deletion of osteopontin reduced formation of abdominal aortic aneurysms (AAA) in mice infused with angiotensin II. 8